Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ANAVEX2-73

Small molecule · developed by Anavex Life Sciences

Phase 2/3 Most advanced trial (none active)
AVXL Developer
2 Registered trials

What is ANAVEX2-73?

ANAVEX2-73 is an oral drug given as 30 mg and 50 mg hard gelatin capsules. It is studied in Alzheimer's disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Neurology
Developer
Anavex Life Sciences Corp. (AVXL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03790709 Phase 2/3 Alzheimer Disease Completed AVXL
NCT02244541 Phase 2 Alzheimer's Disease Completed AVXL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alzheimer DiseaseAlzheimer's Disease

More from Anavex Life Sciences

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the AVXL page.

Follow AVXL, the company behind ANAVEX2-73

See AVXL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AVXL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.